BRIEF-Amphastar Pharmaceuticals- Nanjing Pharmaceuticals Enters Supply Agreement With Nanjing Letop Biotechnology On March 3 - SEC Filing

Reuters03-07

BRIEF-<a href="https://laohu8.com/S/AMPH">Amphastar Pharmaceuticals</a>- Nanjing Pharmaceuticals Enters Supply Agreement With Nanjing Letop Biotechnology On March 3 - SEC Filing

March 6 (Reuters) - Amphastar Pharmaceuticals Inc AMPH.O:

AMPHASTAR PHARMACEUTICALS- NANJING PHARMACEUTICALS ENTERS SUPPLY AGREEMENT WITH NANJING LETOP BIOTECHNOLOGY ON MARCH 3- SEC FILING
AMPHASTAR PHARMACEUTICALS INC - SUPPLY AGREEMENT EFFECTIVE FOR FIVE YEARS WITH PAYMENTS IN CHINESE YUAN - SEC FILING
AMPHASTAR PHARMACEUTICALS: ON MARCH 3, CO & NANJING HANXIN PHARMACEUTICAL TECHNOLOGY ENTERED INTO AMENDMENT TO CONTRACT RESEARCH AGREEMENT
AMPHASTAR PHARMACEUTICALS: PURSUANT TO AMENDMENT, CO TO USE RESEARCH CELL BANKS THAT HANXIN DEVELOPS TO MAKE MASTER CELL BANKS FOR AMP-105

Further company coverage: AMPH.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2617580276?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-07 05:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617580276","market":"nz","top_or_hot":-1,"title":"BRIEF-Amphastar Pharmaceuticals- Nanjing Pharmaceuticals Enters Supply Agreement With Nanjing Letop Biotechnology On March 3 - SEC Filing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/AMPH\">Amphastar Pharmaceuticals</a>- Nanjing Pharmaceuticals Enters Supply Agreement With Nanjing Letop Biotechnology On March 3 - SEC Filing</title></head><body><p><span>March 6 (Reuters)</span><span> - </span>Amphastar Pharmaceuticals Inc <span>AMPH.O</span>:</p><ul><li><p>AMPHASTAR PHARMACEUTICALS- NANJING PHARMACEUTICALS ENTERS SUPPLY AGREEMENT WITH NANJING LETOP BIOTECHNOLOGY ON MARCH 3- SEC FILING</p></li><li><p>AMPHASTAR PHARMACEUTICALS INC - SUPPLY AGREEMENT EFFECTIVE FOR FIVE YEARS WITH PAYMENTS IN CHINESE YUAN - SEC FILING</p></li><li><p>AMPHASTAR PHARMACEUTICALS: ON MARCH 3, CO &amp; NANJING HANXIN PHARMACEUTICAL TECHNOLOGY  ENTERED INTO AMENDMENT TO CONTRACT RESEARCH AGREEMENT</p></li><li><p>AMPHASTAR PHARMACEUTICALS: PURSUANT TO AMENDMENT, CO TO USE RESEARCH CELL BANKS THAT HANXIN DEVELOPS TO MAKE MASTER CELL BANKS FOR AMP-105</p></li></ul><p>Further company coverage: <span>AMPH.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Amphastar Pharmaceuticals- Nanjing Pharmaceuticals Enters Supply Agreement With Nanjing Letop Biotechnology On March 3 - SEC Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Amphastar Pharmaceuticals- Nanjing Pharmaceuticals Enters Supply Agreement With Nanjing Letop Biotechnology On March 3 - SEC Filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-07 05:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/AMPH\">Amphastar Pharmaceuticals</a>- Nanjing Pharmaceuticals Enters Supply Agreement With Nanjing Letop Biotechnology On March 3 - SEC Filing</title></head><body><p><span>March 6 (Reuters)</span><span> - </span>Amphastar Pharmaceuticals Inc <span>AMPH.O</span>:</p><ul><li><p>AMPHASTAR PHARMACEUTICALS- NANJING PHARMACEUTICALS ENTERS SUPPLY AGREEMENT WITH NANJING LETOP BIOTECHNOLOGY ON MARCH 3- SEC FILING</p></li><li><p>AMPHASTAR PHARMACEUTICALS INC - SUPPLY AGREEMENT EFFECTIVE FOR FIVE YEARS WITH PAYMENTS IN CHINESE YUAN - SEC FILING</p></li><li><p>AMPHASTAR PHARMACEUTICALS: ON MARCH 3, CO &amp; NANJING HANXIN PHARMACEUTICAL TECHNOLOGY  ENTERED INTO AMENDMENT TO CONTRACT RESEARCH AGREEMENT</p></li><li><p>AMPHASTAR PHARMACEUTICALS: PURSUANT TO AMENDMENT, CO TO USE RESEARCH CELL BANKS THAT HANXIN DEVELOPS TO MAKE MASTER CELL BANKS FOR AMP-105</p></li></ul><p>Further company coverage: <span>AMPH.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4557","symbol_name":"大麻股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nFWN3ZU0UG:1","article_id":"2617580276","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617580276","pubTimestamp":1772833852,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Amphastar Pharmaceuticals- Nanjing Pharmaceuticals Enters Supply Agreement With Nanjing Letop Biotechnology On March 3 - SEC FilingMarch 6  - Amphastar Pharmaceuticals Inc AMPH.O:AMPHASTAR PHARMACEUTICALS- NANJING PHARMACEUTICALS ENTERS SUPPLY AGREEMENT WITH NANJING LETOP BIOTECHNOLOGY ON MARCH 3- SEC FILINGAMPHASTAR PHARMACEUTICALS INC - SUPPLY AGREEMENT EFFECTIVE FOR FIVE YEARS WITH PAYMENTS IN CHINESE YUAN - SEC FILINGAMPHASTAR PHARMACEUTICALS: ON MARCH 3, CO & NANJING HANXIN PHARMACEUTICAL TECHNOLOGY  ENTERED INTO AMENDMENT TO CONTRACT RESEARCH AGREEMENTAMPHASTAR PHARMACEUTICALS: PURSUANT TO AMENDMENT, CO TO USE RESEARCH CELL BANKS THAT HANXIN DEVELOPS TO MAKE MASTER CELL BANKS FOR AMP-105Further company coverage: AMPH.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4557":"大麻股","AMPH":"Amphastar Pharmaceuticals","BK4007":"制药","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"简介-Amphastar Pharmaceuticals-南京医药于3月3日与南京乐拓生物科技签订供应协议-SEC备案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMPH":0.9},"content_text":"BRIEF-Amphastar Pharmaceuticals- Nanjing Pharmaceuticals Enters Supply Agreement With Nanjing Letop Biotechnology On March 3 - SEC FilingMarch 6 (Reuters) - Amphastar Pharmaceuticals Inc AMPH.O:AMPHASTAR PHARMACEUTICALS- NANJING PHARMACEUTICALS ENTERS SUPPLY AGREEMENT WITH NANJING LETOP BIOTECHNOLOGY ON MARCH 3- SEC FILINGAMPHASTAR PHARMACEUTICALS INC - SUPPLY AGREEMENT EFFECTIVE FOR FIVE YEARS WITH PAYMENTS IN CHINESE YUAN - SEC FILINGAMPHASTAR PHARMACEUTICALS: ON MARCH 3, CO & NANJING HANXIN PHARMACEUTICAL TECHNOLOGY  ENTERED INTO AMENDMENT TO CONTRACT RESEARCH AGREEMENTAMPHASTAR PHARMACEUTICALS: PURSUANT TO AMENDMENT, CO TO USE RESEARCH CELL BANKS THAT HANXIN DEVELOPS TO MAKE MASTER CELL BANKS FOR AMP-105Further company coverage: AMPH.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617580276","isCrawlerRequest":true}